It is crucial to achieve a comprehensive understanding of the negative regulators of p38 signaling in COPD to develop innovative therapeutic strategies for COPD and identify potential therapeutic targets. This evidence concerns the gene MAPK1 and chronic obstructive pulmonary disease.